阿尔伯塔大学跨学科团队在《The Conversation》解释,含semaglutide的GLP-1药物对个体影响并不相同,遗传、年龄、身体组成、生活方式及其他疾病等因素都可能有关。文章引述一项配合生活方式干预、持续68周的研究平均减重约15%,但平均数不代表每个人都会达到。

团队关注“代谢适应”:减重后身体较小本来需要较少能量,有时耗能还会低于按体重变化预计的程度。其综述发现,关于semaglutide与静息耗能的少量研究结果中性或不明确,不能据此宣称药物必然降低或提高代谢。

研究人员计划利用整室间接测热设施,跟踪即将开始治疗且有血糖调节问题的参与者六个月,观察体重、身体组成及能量使用。文章属于研究进展解读,尚未提供能预测个人疗效的成熟工具,也不能代替处方评估。

来源:The Conversation(观点/分析) 原报道。大鱼新闻整理原创中文摘要;保留原刊发日期。

司美格鲁肽注射笔示意图,Unsplash+。

司美格鲁肽注射笔示意图,Unsplash+。

Obesity medication is an important pillar of obesity management and should be monitored as part of a comprehensive, multidisciplinary approach to care. (Obesity Canada) , CC BY-NC-ND

Obesity medication is an important pillar of obesity management and should be monitored as part of a comprehensive, multidisciplinary approach to care. (Obesity Canada) , CC BY-NC-ND

Current guidelines recommend people using GLP-1 medications to engage in resistance exercise to optimize their body composition for the best results. (Obesity Canada) , CC BY-NC-ND

Current guidelines recommend people using GLP-1 medications to engage in resistance exercise to optimize their body composition for the best results. (Obesity Canada) , CC BY-NC-ND